

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP**

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden	
hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Atlas Venture Fund X, L.P.</u>  (Last) (First) (Middle) 400 TECHNOLOGY SQUARE, 10TH FLOOR  (Street) CAMBRIDGE MA 02139  (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>AVROBIO, Inc. [ AVRO ]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  Director <input checked="" type="checkbox"/> 10% Owner Officer (give title below) <input type="checkbox"/> Other (specify below)
	3. Date of Earliest Transaction (Month/Day/Year) 06/25/2018	
4. If Amendment, Date of Original Filed (Month/Day/Year)		

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	06/25/2018		C		806,711	A	(1)	806,711	I	See Footnote(2)
Common Stock	06/25/2018		C		3,044,579	A	(3)	3,851,290	I	See Footnote(2)
Common Stock	06/25/2018		C		905,188	A	(4)	4,756,478	I	See Footnote(2)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Series Seed Preferred Stock	(3)	06/25/2018		C		3,333,333		(5)	(5)	Common Stock	806,711(5)	\$0.00	0	I	See footnote(2)
Series A Preferred Stock	(3)	06/25/2018		C		12,580,199		(5)	(5)	Common Stock	3,044,579(5)	\$0.00	0	I	See footnote(2)
Series B Preferred Stock	(3)	06/25/2018		C		3,740,239		(5)	(5)	Common Stock	905,188(5)	\$0.00	0	I	See footnote(2)

1. Name and Address of Reporting Person\*  
Atlas Venture Fund X, L.P.  
 (Last) (First) (Middle)  
 400 TECHNOLOGY SQUARE, 10TH FLOOR  
 (Street)  
 CAMBRIDGE MA 02139  
 (City) (State) (Zip)

1. Name and Address of Reporting Person\*  
ATLAS VENTURE ASSOCIATES X, L.P.  
 (Last) (First) (Middle)  
 400 TECHNOLOGY SQUARE, 10TH FLOOR  
 (Street)  
 CAMBRIDGE MA 02139  
 (City) (State) (Zip)

1. Name and Address of Reporting Person\*

Atlas Venture Associates X, LLC

(Last) (First) (Middle)  
400 TECHNOLOGY SQUARE, 10TH FLOOR

(Street)  
CAMBRIDGE MA 02139

(City) (State) (Zip)

**Explanation of Responses:**

1. Represents the total number of shares of Common Stock received by Atlas Venture Fund X, L.P. ("Atlas Venture Fund X"), upon the conversion of the Issuer's Series Seed Preferred Stock in connection with the closing of the Issuer's initial public offering.
2. The shares are held directly by Atlas Venture Fund X. The general partner of Atlas Venture Fund X is Atlas Venture Associates X, L.P. ("AVA X LP"). Atlas Venture Associates X, LLC ("AVA X LLC") is the general partner of AVA X LP. Each of AVA X LP and AVA X LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund X, except to the extent of its pecuniary interest therein, if any.
3. Represents the total number of shares of Common Stock received by Atlas Venture Fund X upon the conversion of the Issuer's Series A Preferred Stock in connection with the closing of the Issuer's initial public offering.
4. Represents the total number of shares of Common Stock received by Atlas Venture Fund X upon the conversion of the Issuer's Series B Preferred Stock in connection with the closing of the Issuer's initial public offering.
5. All series of Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 4.132-for-1 basis on June 25, 2018 and had no expiration date.

**Remarks:**

Atlas Venture Fund X, L.P., By:  
Atlas Venture Associates X, L.P.,  
it's general partner, By: Atlas  
Venture Associates X, LLC, its 06/25/2018  
general partner, By: Ommer  
Chohan, Chief Financial Officer,  
/s/ Ommer Chohan

Atlas Venture Associates X, L.P.,  
By: Atlas Venture Associates X,  
LLC, it's general partner, By: 06/25/2018  
Ommer Chohan, Chief Financial  
Officer, /s/ Ommer Chohan

Atlas Venture Associates X,  
LLC, By: Ommer Chohan, Chief 06/25/2018  
Financial Officer, /s/ Ommer  
Chohan

\*\* Signature of Reporting Person      Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.